Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Huntington Ingalls Industries Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Huntington Ingalls Industries Inc for 28 Days on average.
| HALO | HII | |
|---|---|---|
Market Cap | $12.58B | $10.44B |
Volume | 2,179,278 | 440,462 |
Sector | Health | Industrials |
52-Week High | $115.22 | $453.73 |
52-Week Low | $61.63 | $257.05 |
Typical Hold Time | 1 Days | 28 Days |
Enterprise Value | $14.49B | $13.37B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HII trades at $265.02, up 1.67% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with a $57.3B backlog, 5.01% net margin, and attractive valuation at P/E 15.78. Recent contract wins including the $5.1B Truman RCOH and 10 ROMULUS USVs provide revenue visibility. Technical indicators show resistance at $268 with support at $261, while moving averages signal bearish pressure.
HII presents a compelling value opportunity with analyst consensus target of $363.67 (37% upside) and 40.74% buy ratings. Strong defense budget tailwinds and contract momentum offset near-term technical weakness. Risks include execution challenges on large contracts and defense spending volatility. The stock offers defensive exposure with dividend yield and consistent earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
